ERBB2 and breast carcinoma: In view of the upcoming launch of the antibody–drug conjugate trastuzumab deruxtecan for HER2-low breast cancer patients, the missing correlation between different anatomic sites and the level of HER2 expression underlines the importance of a biopsy-based re-evaluation of HER2 expression of a breast cancer metastasis irrespective of the anatomical site.